Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Viz.ai Awarded Best New Radiology Software

Viz.ai
Posted on: 25 Oct 18

Viz.ai has received the 2018 Best New Radiology Software Minnies award for Viz LVO, the first FDA cleared AI-based clinical decision support software designed to analyze computed tomography (CT) images and notify providers of a potential stroke in their patients. The Minnies are an annual event recognizing excellence in medical imaging..

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181025005549/en/

Minnies winners were selected by an expert panel during two rounds of voting with 220 companies spanning 14 categories designed to recognize the best and brightest in medical imaging. The panel selected from a field of 28 semi-finalists ranging from small start-ups to large corporations.

"The Minnies recognizes the best and brightest in medical imaging and sets the direction for the future of radiology.” said Dr. Chris Mansi, neurosurgeon and Viz.ai CEO. “If the past is any indication of the future, the innovations recognized by receiving a Minnies award will soon be considered the ‘new normal’ in the field of radiology.”

The winning software, Viz LVO, is revolutionizing stroke management and workflow with a cloud-based artificial intelligence system that automatically analyzes CT scans for large vessel occlusions (LVO). It alerts neurovascular specialists of a suspected LVO, enabling earlier imaging review and better collaboration between specialists. The AI analysis, performed by deep learning algorithms, works alongside physicians and helps to get the right patient to the right doctor at the right time.

“We’re pleased to present the 2018 Minnies award for Best New Radiology Software to Viz.ai for its Viz LVO software,” said Brian Casey, Editor in Chief of AuntMinnie.com. “This solution exemplifies how a new generation of artificial intelligence-based technology has the potential to revolutionize radiology by providing support and guidance to radiologists as they do their jobs.”

The only stroke triage software to receive FDA clearance, Viz LVO combines groundbreaking Artificial Intelligence with frictionless communication. Viz.ai software provides the resources that can save critical minutes, even hours, in the triage, diagnosis and treatment of stroke and allows specialists to be proactive rather than reactive. Viz LVO facilitates fast and accurate detection and referral of suspected large vessel occlusion stroke patients enabling better collaboration between clinicians at comprehensive and referral hospitals.

The 2018 Minnies Best New Radiology Software award is another recognition of Viz.ai’s industry leading artificial intelligence software.

About Stroke

Stroke is a leading cause of permanent disability, death and healthcare costs globally. According to the American Heart Association/American Stroke Association (AHA/ASA), stroke is the fifth leading cause of death in the U.S. and a leading cause of disability. When a stroke occurs, and the flow of oxygen-rich blood to a portion of the brain is blocked, two million brain cells die every minute; in the case of stroke, "time is brain."

About Viz.ai, Inc.

Viz.ai, is the leader in applied artificial intelligence in healthcare. Viz.ai’s mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care.

Viz.ai’s flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat.

In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification software. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral image analysis.

Viz.ai is located in San Francisco and Tel Aviv and backed by leading Silicon Valley investors, including Kleiner Perkins, Google Ventures, Innovation Endeavors and DHVC.

To find out more, visit http://www.Viz.ai, follow us on Twitter or find us on LinkedIn.

Viz LVO and Viz CTP indications of use can be found at https://www.viz.ai/indications-for-use/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181025005549/en/

Business Wire
www.businesswire.com

Last updated on: 25/10/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.